Victoria DiBiaso

Thanks to a global effort focusing on reducing site burden, Sanofi rose to the #1 position in the CenterWatch Survey in 2019. This was the biggest jump any sponsor had achieved in consecutive surveys. In parallel, Sanofi has continued their patient-informed R&D model, bringing the patient voice into each of their programs. This has been the catalyst for various award-winning recognitions and further supported accelerated medicines development.

Sanofi Making Investigators Lives Easier (SMILE)

Launched in 2017, the “whole objective [of SMILE] was to positively innovate the way we conduct our clinical trials from a site-centric perspective,” DiBiaso says. Before kicking off the program, though, Sanofi took time to really look at clinical trial efficiencies with an eye toward improving them from the perspective of reducing the burden of clinical research to make it easier for sites and patients to contribute to a greater… Voir plus

Sanofi Making Investigators Lives Easier (SMILE)

Launched in 2017, the “whole objective [of SMILE] was to positively innovate the way we conduct our clinical trials from a site-centric perspective,” DiBiaso says. Before kicking off the program, though, Sanofi took time to really look at clinical trial efficiencies with an eye toward improving them from the perspective of reducing the burden of clinical research to make it easier for sites and patients to contribute to a greater extent.

“We have some extremely beneficial programs [that might ultimately] address true unmet medical needs for patients,” especially in the arenas of oncology and rare blood and genetic disorders, DiBiaso says. “It is our ethical obligation to run these studies faster so that [the end result] is either life-saving or improves quality of life,” she adds. Voir moins

"We're at a stage of true transformation", said DiBiaso

Association of Clinical Research Professionals

Contributor and quoted in "The Long Wave Goodbye to Phantom PIs. FDA & Industry tackling disengaged PIs but more to be done." by Suz Redfearn

Guest speaker for the 20th Anniversary Symposium on Clinical Research.

This post was authored by Victoria DiBiaso, Associate Vice President, Head, Office of Patient Participation & Preferred Partnerships, Sanofi.

Patients today aren’t just taking part in clinical trials – they are also playing an increasing role in their design and development. This is an important step forward in the clinical trial process; as patient input helps companies better understand the perspective of those living with the disease being studied, which can ultimately help refine… Voir plus

This post was authored by Victoria DiBiaso, Associate Vice President, Head, Office of Patient Participation & Preferred Partnerships, Sanofi.

Patients today aren’t just taking part in clinical trials – they are also playing an increasing role in their design and development. This is an important step forward in the clinical trial process; as patient input helps companies better understand the perspective of those living with the disease being studied, which can ultimately help refine our study designs and operational approach to boost recruitment. Voir moins

"Victoria DiBiaso, AVP and Head of the Office of Patient Participation, at Sanofi & Genzyme explains their model and culture as hands on engagement with the most important concerns of patients and patient advocate associations. A set of guiding principles for collaboration ensures that values are lived out in relationships with patient organizations. The engagement of patient advocates and groups can start as early as the pre-clinical stage where their input is solicited to determine if the… Voir plus

"Victoria DiBiaso, AVP and Head of the Office of Patient Participation, at Sanofi & Genzyme explains their model and culture as hands on engagement with the most important concerns of patients and patient advocate associations. A set of guiding principles for collaboration ensures that values are lived out in relationships with patient organizations. The engagement of patient advocates and groups can start as early as the pre-clinical stage where their input is solicited to determine if the asset is efficacious and important to patients.

In development programs, Sanofi (inclusive of Genzyme) frequently tests the study design with patient advocate groups and physicians to understand the challenges from the perspective of the patient in order to identify ways to make the study experience less burdensome and complex...." Voir moins

"Vicky DiBiaso, head of Sanofi's Office of Patient Participation and Preferred Partnerships, says trial-design input is being sought from patients in drug trialsthe company is running in six major diseases, including diabetes and cancer. Two studies have finished the recruitment phase- an asthma study enrolled two months early and a study in diabetes enrolled two and a half weeks early. She attributed the rapid recruitment at least in part to patient participation and a better understanding of… Voir plus

"Vicky DiBiaso, head of Sanofi's Office of Patient Participation and Preferred Partnerships, says trial-design input is being sought from patients in drug trialsthe company is running in six major diseases, including diabetes and cancer. Two studies have finished the recruitment phase- an asthma study enrolled two months early and a study in diabetes enrolled two and a half weeks early. She attributed the rapid recruitment at least in part to patient participation and a better understanding of 'the perspective of those living with the disease so we can make it easier for patient to become involved'". Voir moins

In May 2013, PatientsLikeMe was asked by Paris-based Sanofi and the nonprofit Center for Information and Study on Clinical Research Participation (CISCRP) in Boston to increase patient awareness of clinical trials for medicines to treat asthma, cancer, diabetes and cardiovascular disease. This collaboration is designed to allow Sanofi to recruit patients across a wide range of geography, age, severity of disease, clinical history and treatment experience.

“Most people do not know what… Voir plus

In May 2013, PatientsLikeMe was asked by Paris-based Sanofi and the nonprofit Center for Information and Study on Clinical Research Participation (CISCRP) in Boston to increase patient awareness of clinical trials for medicines to treat asthma, cancer, diabetes and cardiovascular disease. This collaboration is designed to allow Sanofi to recruit patients across a wide range of geography, age, severity of disease, clinical history and treatment experience.

“Most people do not know what clinical trials are,” says Victoria DiBiaso, Sanofi’s head of investigative and patient networks, from her office in Cambridge, Massachusetts. “They don’t know that it’s even an option.”

DiBiaso dreams of big results. “What I really hope will come from this is the understanding that clinical research is what drives the medicines of tomorrow and that the people who take part in them are really medical heroes,” she says. “Without them, we can’t advance to the next cure.”
Voir moins

"PatientsLikeMe and the nonprofit Center for the Information and Study on Clinical Trial Participation (CISCRP) have formed a new partnership with global healthcare company Sanofi to raise public awareness about the benefits of clinical trial participation".

"We must help improve clinical trial literacy, said Vicky DiBiaso, senior director and head of investigator and site networks at Sanofi."The general public does not yet truly understand the value of the gift to society by these… Voir plus

"PatientsLikeMe and the nonprofit Center for the Information and Study on Clinical Trial Participation (CISCRP) have formed a new partnership with global healthcare company Sanofi to raise public awareness about the benefits of clinical trial participation".

"We must help improve clinical trial literacy, said Vicky DiBiaso, senior director and head of investigator and site networks at Sanofi."The general public does not yet truly understand the value of the gift to society by these individuals. This needs to change. We look forward to the day when people who volunteer their time to participate in the clinical research process are admired and recognized by their neighbors, friends and colleages as the 'Medical Heroes' they truly are". Voir moins

Launched in 2017, the “whole objective [of SMILE] was to positively innovate the way we conduct our clinical trials from a site-centric perspective,” DiBiaso says. Before kicking off the program, though, Sanofi took time to really look at clinical trial efficiencies with an eye toward improving them from the perspective of reducing the burden of clinical research to make it easier for sites and patients to contribute to a greater extent.

“We have some extremely beneficial programs [that… Voir plus

Launched in 2017, the “whole objective [of SMILE] was to positively innovate the way we conduct our clinical trials from a site-centric perspective,” DiBiaso says. Before kicking off the program, though, Sanofi took time to really look at clinical trial efficiencies with an eye toward improving them from the perspective of reducing the burden of clinical research to make it easier for sites and patients to contribute to a greater extent.

“We have some extremely beneficial programs [that might ultimately] address true unmet medical needs for patients,” especially in the arenas of oncology and rare blood and genetic disorders, DiBiaso says. “It is our ethical obligation to run these studies faster so that [the end result] is either life-saving or improves quality of life,” she adds. Voir moins

PALADIN is a first of its kind consortium bringing patient advocacy leaders and the drug development industry together as a network to find ways to transform the pace of medicines development.